Vernalis plc: V3381 Programme Update

Vernalis plc: V3381 Programme Update

18 November 2010

LSE: VER

Vernalis plc today announces its decision to cease further investment in V3381.

An interim review of data from the small pilot study in chronic cough being undertaken in collaboration with Professor Ashley Woodcock from the University Hospitals of South Manchester NHS Foundation revealed only marginal efficacy and some issues with tolerability.  Following consideration of these results and the previously announced results of the IN-STEP Phase IIb study in neuropathic pain no further investment will be made by Vernalis in V3381.

 

-- ends --

Enquiries:

Vernalis Contacts

 
 
 
Ian Garland, Chief Executive Officer
 +44 (0) 118 989 9360
 
David Mackney, Chief Financial Officer

 
 
 
Brunswick Group

 
 
 
Jon Coles
 +44 (0) 20 7404 5959
 
Justine McIlroy
 
 
 
 
 
Taylor Rafferty

 
 
 
Rob Newman
 +44 (0) 20 7614 2900
 
Faisal Kanth
  
 

 

Notes to Editors

About Vernalis

Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market.  The Group has one marketed product, frovatriptan for the acute treatment of migraine, and nine candidates in development, six of which are designated priority programmes.  Three of these priority programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations.  Our technologies, capabilities and products are endorsed by collaborations with Biogen Idec, Chiesi, Endo, GSK, Menarini, Novartis and Servier.

 

Product
 Indication
 Pre-Clinical
 Phase I
 Phase II
 Phase III
 Marketed
 Marketing Rights
 
Priority Programmes
 
 
 
 
 
 
 
CNS Programmes
 
 
 
 
 
 
 
Frovatriptan
 Acute Migraine
 
 
 
 
 X
 Menarini & Endo Pharma
 
2nd generation A2A antagonist
 Parkinson's Disease
 X
 
 
 
 
 Biogen Idec
 
V158866
 Pain
 X
 
 
 
 
 Worldwide
 
Oncology Programmes
 
 
 
 
 
 
 
AUY922
 Cancer
 
 
 X
 
 
 Novartis
 
HSP990
 Cancer
 
 X
 
 
 
 Novartis
 
V158411
 Cancer
 X
 
 
 
 
 Worldwide
 
Other Therapeutic Areas
 
 
 
 
 
 
 
V85546
 Inflammatory Disease
 
 X
 
 
 
 Worldwide
 
Legacy programmes
 
 
 
 
 
 
 
V10153
 Ischaemic Stroke
 
 
 X
 
 
 Worldwide
 
RPL554
 Asthma/ Allergic Rhinitis
 
 
 X
 
 
 Verona Pharma
 
CHR2797
 Cancer
 
 
 X
 
 
 Chroma Therapeutics
 

 

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova® and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.